Your shopping cart is currently empty

S65487 (VOB560) is a potent and selective inhibitor of the anti-apoptotic protein Bcl-2, displaying activity not only against the wild-type protein but also against clinically relevant BCL-2 mutations such as G101V and D103Y. S65487 demonstrates poor affinity toward other Bcl-2 family members, including MCL-1, BFL-1, and BCL-XL, which underlines its selectivity profile. S65487 induces apoptosis in cancer cells and exhibits robust anticancer activities in preclinical studies.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $139 | - | In Stock | |
| 5 mg | $347 | - | In Stock | |
| 10 mg | $579 | - | In Stock | |
| 25 mg | $1,160 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $548 | - | In Stock |
| Description | S65487 (VOB560) is a potent and selective inhibitor of the anti-apoptotic protein Bcl-2, displaying activity not only against the wild-type protein but also against clinically relevant BCL-2 mutations such as G101V and D103Y. S65487 demonstrates poor affinity toward other Bcl-2 family members, including MCL-1, BFL-1, and BCL-XL, which underlines its selectivity profile. S65487 induces apoptosis in cancer cells and exhibits robust anticancer activities in preclinical studies. |
| In vitro | S65487 effectively induces apoptosis and inhibits proliferation in a panel of hematologic cancer cell lines by binding to the BH3 hydrophobic groove of the BCL-2 protein, with a half-maximal inhibitory concentration (IC50) in the low nanomolar (nM) range. [1] |
| In vivo | S65487 effectively induces complete regression in BCL-2-dependent RS4;11 tumors through a single intravenous (IV) dose and demonstrates consistent, strong tumor regression in mouse and rat xenograft models of lymphoid malignancies at tolerable doses with weekly IV administrations when combined with MCL-1-specific inhibitor S64315/MIK665.[1] |
| Synonyms | VOB560, VOB 560 |
| Molecular Weight | 717.26 |
| Formula | C41H41ClN6O4 |
| Cas No. | 1644600-79-2 |
| Smiles | N(C(=O)C=1C=C(N(C)C1C)C2=C(C(=O)N3[C@H](CN4CCOCC4)CC=5C(C3)=CC=CC5)C=CC(Cl)=C2)(C=6C=C(C#N)N(C)C6C)C7=CC=C(O)C=C7 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 160 mg/mL (223.07 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (6.97 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.